Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. With a market capitalization of $736.1M, it sits in small-cap territory. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Market Cap
$736.1M
Beta
0.20
P/E (TTM)
—
P/E (Fwd)
-6.00
EPS (TTM)
$-2.01
EPS (Fwd)
$-2.03
ROE
-52.7%
ROA
-23.3%
Cash
$222.0M
Total Debt
$2.2M
Free CF
-$27.8M
52W Change
-30.3%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $222.0M in cash comfortably exceeding the $2.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$27.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -52.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
OCS's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, OCS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Oculis Holding AG's trajectory.